Synthesis and Pharmacology of Clinical Drugs Containing Isoindoline Heterocycle Core

References (73)

1. 1 Youssef, 2021, Pharmacology and synthesis of clinical drugs containing isoquinoline core
2. 2 Kabir, 2022, A review on biological and medicinal impact of heterocyclic compounds [DOI]
3. 3 Ruiz, 2010, Production of microbial secondary metabolites: Regulation by the carbon source [DOI]
4. 4 Kaur, 2022, How do plants defend themselves against pathogens-biochemical mechanisms and genetic interventions [DOI]
5. 5 Han, 2017, recent advances in the synthesis of biologically active cinnoline, phthalazine and quinoxaline derivatives [DOI]
6. 6 Clary, 2009, Preparation of 1-aryl-substituted isoindoline derivatives by sequential Morita–Baylis–Hillman and intramolecular Diels–Alder reactions [DOI]
7. 7 Thakur, A., Singh, A., Kaur, N., Ojha, R., and Nepali, K. (2020). Steering the antitumor drug discovery campaign towards structurally diverse indolines. Bioorg. Chem., 94. [DOI]
8. 8 Upadhyay, 2020, 1-Isoindolinone Scaffold-Based Natural Products with a Promising Diverse Bioactivity [DOI]
9. 9 Barragan, 2025, Phthalimides as Anti-Inflammatory Agents [DOI]
10. 10 Starosotnikov, 2017, Cycloaddition reactions in the synthesis of isoindolines [DOI]
11. 11 Williams, 2011, Palladium-catalyzed cascade reaction for the synthesis of substituted isoindolines [DOI]
12. 12 Ward, 1962, Thalidomide and congenital abnormalities [DOI]
13. 13 Weagle, 2017, Convenient access to 5-arylisoindolo[2,1-a]quinolin-11(6aH)-ones [DOI]
14. 14 Jha, 2014, Aza-Diels–Alder reaction between N-aryl-1-oxo-1H-isoindolium ions and tert-enamides: Steric effects on reaction outcome [DOI]
15. 15 Mohapatra, 2016, Expedient and diastereoselective synthesis of substituted 6,6a-dihydroisoindolo[2,1-a]quinolin-11(5H)-ones [DOI]
16. 16 Mohapatra, 2016, Facile synthesis of 3-substituted isoindolinones [DOI]
17. 17 Brandenburg, 2017, Effectiveness of risk evaluation and mitigation strategies (REMS) for lenalidomide and thalidomide: Patient comprehension and knowledge retention [DOI]
18. 18 Kim, 2011, Thalidomide: The tragedy of birth defects and the effective treatment of disease [DOI]
19. 19 Ali, 2012, Thalidomide: A banned drug resurged into future anticancer drug [DOI]
20. 20 Anderson, 2005, Lenalidomide and Thalidomide: Mechanisms of action—Similarities and differences [DOI]
21. 21 Udeshi, 2014, Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells [DOI]
22. 22 Majumder, 2012, TNF-α signaling beholds thalidomide saga: A review of mechanistic role of TNF-α signaling under thalidomide [DOI]
23. 23 Chamberlain, 2019, Cereblon Modulators: Low molecular weight inducers of protein degradation [DOI]
24. 24 Muller, 1999, A concise two-step synthesis of thalidomide [DOI]
25. 25 Eguchi, S. (2007). Synthesis of thalidomide. Bioactive Heterocycles II, Springer. [DOI]
26. 26 Mousa, S.A., and Davis, P.J. (2017). Chapter 3—Anti-angiogenesis in multiple myeloma. Anti-Angiogenesis Strategies in Cancer Therapeutics, Academic Press. [DOI]
27. 27 Jaeger, H.K., Davis, D.A., Nair, A., Shrestha, P., Stream, A., Yaparla, A., and Yarchoan, R. (2023). Mechanism and therapeutic implications of pomalidomide-induced immune surface marker upregulation in EBV-positive lymphomas. Sci. Rep., 13. [DOI]
28. 28 Swaika, 2013, Pomalidomide: The new immunomodulatory agent for the treatment of multiple myeloma [DOI]
29. 29 Ding, 2015, Synthetic approaches to the 2013 new drugs [DOI]
30. 30 Fala, 2015, Otezla (Apremilast), an Oral PDE-4 inhibitor, receives fda approval for the treatment of patients with active psoriatic arthritis and plaque psoriasis
31. 31 Hatemi, 2022, Impact of apremilast on quality of life in Behçet’s syndrome: Analysis of the phase 3 RELIEF study [DOI]
32. 32 Fertig, B.A., and Baillie, G.S. (2018). PDE4-mediated cAMP signalling. J. Cardiovasc. Dev. Dis., 5. [DOI]
33. 33 Tong, B.N., Liu, X.L., Xiao, J., and Su, G.F. (2019). Immunopathogenesis of Behcet’s disease. Front. Immunol., 10. [DOI]
34. 34 Narode, 2021, A review on synthetic advances toward the synthesis of apremilast, an anti-inflammatory drug [DOI]
35. 35 Pohanish, R.P. (2015). Sittig’s Handbook of Pesticides and Agricultural Chemicals, William Andrew Publishing. [2nd ed.]. [DOI]
36. 36 Morgan, R.V. (2008). CHAPTER 125—Insecticides and Molluscicides. Handbook of Small Animal Practice, W.B. Saunders. [5th ed.].
37. 37 Müller, F., Streibert, H.P., and Farooq, S. (2009). Acaricides. Ullmann’s Encyclopedia of Industrial Chemistry, Woley-VCH Verlag GmbH & Co. [DOI]
38. 38 Qiao, 2015, Efficacy and safety of lenalidomide in the treatment of multiple myeloma: A systematic review and meta-analysis of randomized controlled trials [DOI]
39. 39 Arora, 2016, A comprehensive review of lenalidomide in B-cell non-Hodgkin lymphoma [DOI]
40. 40 Muller, 1999, Amino-substituted thalidomide analogs: Potent inhibitors of TNF-α production [DOI]
41. 41 Kotla, 2009, Mechanism of action of lenalidomide in hematological malignancies [DOI]
42. 42 Hui, 2022, Embryo-fetal exposure and developmental outcome of lenalidomide following oral administration to pregnant cynomolgus monkeys [DOI]
43. 43 Galustian, 2009, Lenalidomide: A Novel Anticancer Drug with Multiple Modalities [DOI]
44. 44 Carroll, 2005, Better drug discovery through better target identification
45. 45 Love, 1985, Indoprofen, a non-steroidal anti-inflammatory analgesic which does not depress respiration in normal man. A study comparing indoprofen with morphine
46. 46 Cashman, 1996, The mechanisms of action of NSAIDs in analgesia [DOI]
47. 47 Kim, 2020, Indoprofen prevents muscle wasting in aged mice through activation of PDK1/AKT pathway [DOI]
48. 48 Lunn, 2004, Indoprofen upregulates the survival motor neuron protein through a cyclooxygenase-independent mechanism [DOI]
49. 49 Carney, R.W.J., and de Stevens, G. (1982). Tertiary Aminoacids. (4,316,850), U.S. Patent.
50. 50 Nannini, 1973, New analgesic-anti-inflammatory drugs. 1-Oxo-2-substituted isoindoline derivatives
51. 51 Takahashi, 2016, Application of the mild-condition phthalimidine synthesis with use of 1,2,3-1H-benzotriazole and 2-mercaptoethanol as dual synthetic auxiliaries. Effective synthesis of phthalimidines possessing a variety of substituents at 2-position [DOI]
52. 52 Wright, 1999, Systematic review of antihypertensive therapies: Does the evidence assist in choosing a first-line drug?
53. 53 Shahin, 2016, Mechanisms and pharmacogenetic signals underlying thiazide diuretics blood pressure response [DOI]
54. 54 Graf, 1959, Zur Konstitution von Benzophenon-2-carbonsäure-Derivaten [DOI]
55. 55 Wilfried, G., Erich, S., and Stoll, W.G. (1962). New Isoindoline Derivatives. (3,055,904), U.S. Patent.
56. 56 Golec, F.A., and Auerbach, J. (1982). Intermediates for the Synthesis of Phthalimidines. (4331600), U.S. Patent.
57. 57 Kumar, A., Singh, D., Jadhav, A., and Pandya, D.N. (2005). An Efficient Industrial Process for 3-hydroxy-3(3′-sulfamyl-4′-chlorophenyl)phtalimidine. (Application Publication WO2005065046), International Patent.
58. 58 Gadakar, M., Wagh, G., Wakchaure, Y., Thanasekaran, P., and Punde, D. (2018). Improved Process for the Preparation of Chlorthalidone. (Application Publication WO2018158777), International Patent.
59. 59 Manley, 2018, Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological Malignancies [DOI]
60. 60 Stone, 2018, Midostaurin: Its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis [DOI]
61. 61 Liang, X., Yang, Q., Wu, P., He, C., Yin, L., Xu, F., Yin, Z., Yue, G., Zou, Y., and Li, L. (2021). The synthesis review of the approved tyrosine kinase inhibitors for anticancer therapy in 2015–2020. Bioorg. Chem., 113. [DOI]
62. 62 Li, 2022, Synthesis and Antitumor Activity of Staurosporine Derivatives
63. 63 Scaini, 2014, Effects of acute administration of mazindol on brain energy metabolism in adult mice [DOI]
64. 64 Inoue, 1995, Clinical Studies with Mazindol [DOI]
65. 65 Mazindol (2024, March 11). DrugBank Online. Available online: https://go.drugbank.com/drugs/DB00579.
66. 66 Seibyl, J.P., Krystal, J.H., and Charney, D.S. (1995). Dopamine and Noradrenergic Reuptake Inhibitors in Treatment of Schizophrenia. (5,447,948), U.S. Patent.
67. 67 Berger, S.P. (1993). Dopamine Uptake Inhibitors in Reducing Substance Abuse and/or Craving. (5,217,987), U.S. Patent.
68. 68 Kovacs, B., and Pinegar, L. (2009). Use of Isoindoles for the Treatment of Neurobehavioral Disorders. (Application Publication WO2009155139), International Patent.
69. 69 Aeberli, 1975, 5-aryl-2,3-dihydro-5H-imidazo[2,1-a]isoindol-5-ols. novel class of anorectic agents. [DOI]
70. 70 Bakke, 1957, Chlorisondamine (ecolid) chloride in medical treatment of severe hypertension [DOI]
71. 71 Souza, 2021, Use of chlorisondamine to assess the neurogenic contribution to blood pressure in mice: An evaluation of method [DOI]
72. 72 Rosen, 1957, Tetrachloroisoindolines and related systems. alkylation reactions and inductive Effects [DOI]
73. 73 Zezula, 2006, The high specific activity tritium labeling of the ganglion-blocking nicotinic antagonist chlorisondamine [DOI]

Cited by 22

Showing 11 of 22 known citations — external sources report more than can currently be individually listed.

Related research

• Reasons Why Students Study Medicine: Views of Students at Delta State University Abraka, South-South Nigeria — shares topic coverage
• Harnessing Artificial Intelligence in Healthcare Analytics: From Diagnosis to Treatment Optimization — shares topic coverage
• Exploring Hemophilic Pseudotumors: A Comprehensive Case Series — shares topic coverage
• A Novel Catalytic Synthesis of Flavones under Autoclave Conditions and Comparative Study of Anti-cancer Activity — shares topic coverage
• HPTLC Densitogram Profile of Aqueous Distillate (Arka) from Roots of Boerhaavia diffusa — shares topic coverage